HPV, a sexually transmitted disease caused by the human papillomavirus, is one of the main triggers of cervical cancer. Recently, however, HPV has also been identified as a cause of throat cancer.
The diagnosis can be made by the clinician or the otorhinolaryngologist, through physical examination and subsequent laryngoscopy. The best form of prevention is the HPV vaccine in addition, of course, to the safe practice of oral sex, taking some fundamental precautions such as the use of condoms, which also prevents the transmission of other diseases, including AIDS.
The main symptoms of throat cancer include:
Doubts? Consult your doctor.
Check out the Cura Project Institute donation page and find out how to help! It's just click here!
There is a large gap between the emergence of new effective treatment options in oncology and their incorporation into the SUS. This means that our population does not benefit from medical advances in the same proportion as other countries that invest more in cancer treatment.What is Metastatic Breast Cancer?Metastatic breast cancer is an advanced stage of breast cancer in which the disease has spread to other organs. Although still incurable, the intense research activity on this topic provided great advances in this area, transforming it into a chronic disease (such as diabetes, for example, which is controlled with medicines).How is HER2-positive metastatic breast cancer treated?There are several types of breast cancer. Approximately 20 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} types of the disease are classified as HER2-positive. These tumors have a more aggressive clinical behavior, but great advances have been made in the last 2 decades. For example: according to statistics, with traditional chemotherapy alone the median survival of women is 20 months (1 year and 8 months). With chemotherapy associated with the drug TRASTUZUMAB, a specific antibody against the HER2 protein, this survival increases to 40 months (3.3 years). On the other hand, when treated with chemotherapy + TRASTUZUMAB + PERTUZUMAB (another antibody that also acts on the HER2 protein), the patient's life expectancy is 56 months (4.7 years).Do all HER2-positive breast cancer patients have access to these medications?No! Although there has been scientific evidence of the benefit of trastuzumab in advanced breast cancer since 2001, it has not yet been incorporated into the SUS.How to solve this?CONITEC, the National Commission for the Incorporation of Technologies into the SUS, is the body responsible for determining which treatments are provided by the Unified Health System. At present, there is a public consultation regarding the incorporation of TRASTUZUMAB and the TRASTUZUMAB + PERTUZUMAB “combo” for the treatment of HER2-positive breast cancer in the metastatic setting.HOW TO CONTRIBUTE?After reading the drug/technology technical report, citizens can make their suggestions and comments about the technology evaluated, as well as about the initial recommendation made by CONITEC. These contributions must be entered in the electronic form available on the portal. Participate! (Consultations 13 and 14)http://conitec.gov.br/consultas-publicas
After the high expectations raised regarding the efficacy of phosphoethanolamine in the treatment of cancer from the uncontrolled use of the substance in patients at USP São Carlos, the inclusion of new patients in research initiated in July 2016 was suspended due to lack of benefit. Of the 59 patients evaluated so far, only one, with melanoma, showed a response (there was an objective reduction in tumor size). The researchers conducting the study are now discussing whether the investigation will continue in patients with melanoma. By ethically and transparently testing a hypothesis, clinical research helps doctors and patients to discover what works (and what doesn't) in the treatment of cancer. Read more at: http://g1.globo.com/bemestar/noticia/fosfoetanolamina-instituto-do-cancer-suspende-testes-devido-a-ausencia-de-beneficio-clinico-significativo.ghtml
The AMAZONA III project is a collection of information about new cases of breast cancer in Brazilian women from 24 public and private health institutions, diagnosed as of January 2016, in the States of Amazonas, Bahia, Ceará, Goiás, Paraná, Rio de Janeiro, Rio Grande do Norte, Rio Grande do Sul, Santa Catarina and São Paulo. Three thousand patients will be included, who will be followed up for 5 years after diagnosis.
The main objective of this study is to increase the knowledge of the medical community about this disease in the Brazilian population, considering socio-demographic characteristics, time of diagnosis, types of treatment and survival, with a view to identifying problems and solutions for the early diagnosis and treatment of breast cancer. This study is extremely important for Brazil because this type of neoplasm is the leading cause of cancer death in women in the world. Of the cases in the country, it is most common in the South (74.30/100 thousand) and Southeast (68.08/100 thousand), while its mortality is higher in the North and Northeast regions.
In an interview for the site Combating Cancer, Dr. Carlos Barrios - LACOG Executive Director - talks about the objectives of the Cura Project and the importance of epidemiological and therapeutic research. Check out: [embed] https://youtu.be/vkc2oUG9hro[/embed]
Latin American Cooperative Oncology Group (LACOG) and Breast International Group (BIG) launch a joint program with the participation of the EORTC for Latin American oncologists. With the program, oncologists from Brazil, Uruguay, and Peru must undergo a period of training in coordinating cooperative groups and conducting clinical studies. The experience should result in significant benefits in the development of clinical research in the area of Oncology in Latin America. Learn more: http://www.breastinternationalgroup.org/news/first-clinical-research-management-training-young-oncologists-latin-america/
Article written by Stephen Stefani, Oncologist at the Mother of God Cancer Hospital, Porto Alegre - RS, published on 10/10/2016 by the online newspaper ZH Opinion. October already has its color. Pink has occupied spaces and reminded of the importance of breast cancer. The growing statistics corroborate the clear perception that almost all of us are touched by cancer, in family, friends, or with ourselves. And it is estimated that, this year, nearly 60,000 women will receive the news that they have cancer. Possibly they will undergo surgery, radiation therapy, chemotherapy, hormone therapy, immunotherapy, or some combination of treatment. The World Health Organization (WHO) estimates that the incidence can be reduced by 30 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} avoiding risk factors such as obesity, excessive alcohol use and smoking. Engagement in awareness campaigns has grown, but it is still much richer in social networks and other media than in practical measures. Many women over 40 have not yet had their mammogram, because they make the mistake of thinking that having no symptoms or family history provides sufficient protection. Access to treatments in the public system is lengthy and incomplete. The prices of new drugs are almost unfeasible for the available budget. The reality may not be so rosy, therefore. But we're moving forward. Toxic treatments are being much better tolerated and diseases that were previously incurable are being cured. Scientific research is closer to everyone and talking about the disease is no longer so scary, but we need practical measures. Fundraising initiatives for research such as the Cura Project (www.projectocura.org), which allows tax-deductible donations, offer hope of seeing a less devastating future. People are surviving and fighting so that their neighbors also have access to these advances, in a current that shows that human beings are much better than we often think.
After about four years of fighting a non-Hodgkin lymphoma that didn't respond definitively to any of the treatments that existed until then, at the end of 1997 I was informed that medicine had nothing left to do for me. In other words, the end of the earthly road had come.
A few weeks later, while trying to find some shortcut to continue on the road, I learned that the FDA (the North American agency that controls food and drugs) had approved the experimental human use of a new medication designed for exactly that type of lymphoma. As a biologist passionate about life and as a patient who didn't want to die, I decided to “run after” that last possibility. Almost two decades after being cured, I continue to thank God, the doctors, the researchers, the laboratory test subjects, the lawyers, and also the people and companies that financed the research that resulted in that medication.
I have watched with concern the frightening advance of cancer worldwide, especially in developing countries. In these countries, the challenges are even greater due to the regional specificity of some types of cancer, the scarcity of resources for prevention and early diagnosis, and the lack of a culture of financial support for clinical research, despite the tax benefits provided for all donors - individuals and legal entities.
The Cura Project is an encouragement in this scenario, as it aims precisely to raise resources to support research into new drugs to combat cancer in Brazil. Here we have strict rules for the approval of research by local ethics committees, which are part of a national regulatory network that protects the safety and well-being of each research participant.
The benefits derived from clinical research do not only reach patients who are cured and resume their normal course of life. They also add value to the institutions and professionals involved in their various stages, opening new frontiers of scientific knowledge that will underpin new scientific advances.
Life is priceless. Please help the Cure Project heal lives!
Cristina Santedicola
Biologist, Master in Geology
Salvador Sep 13, 2016
Check out the Cura Project Institute donation page and find out how to help! It's just click here!
On September 24, 2016, the Mother of God Cancer Hospital and the Porto Alegrense Equestrian Society promote 1st Dinner for Cancer Research - Cancer is no match when we work together!
The Dinner seeks to raise funds for the CURA project, which is an initiative of the LACOG (Latin American Cooperative Oncology Group) that proposes the development of actions to raise funds for cancer research in Latin America. The Cura Project makes events a means to raise awareness, educate, and raise funds for cancer research, considered fundamental to the discovery of new treatments for the disease. Dinner has a different proposal where guests will follow an equestrian event in a sophisticated and elegant environment.
Objectives of the event:
Some important information about the event:
Date: September 24, 2016 — Saturday — 7:45 p.m.Local: Sociedade Hípica Porto Alegrense, Av. Juca Batista, 4931 — South Zone - Porto Alegre-RS; valet parking (free of charge)Suit: Full tourTarget audience: 150 people from Sociedade Porto Alegrense
Event schedule: 19:45pm — Cocktail reception for guests 8:30pm — Start of the equestrian event — Jump mode 21:15pm — Official opening 9:45pm — Dinner and auction
You or your company can have the unique satisfaction of attending a dinner for good as part of those who believe that the fight against cancer depends on unity, research, and mobilization.
For more information, contact: Vanessa Patzlaff BrandolfVanessa.brandolf@maededeus.com.brFone: 55 51 9282 4239
The Cure Project was presented at the 11th edition of the Breast Cancer Congress, at the Inertia and Denial Conference: the participation of Brazilian/Latin American society in the fight against cancer.
The conference was held in the city of Gramado, Rio Grande do Sul, and was presented by the Fundraising Coordinator of the Cura Project, Fernanda Schwyter.
Presentation of the Cura Project at the Breast Cancer Congress in Gramado.
From left to right: Laura Voelcker — LACOG Project Manager; Raira Maschmann — LACOG Data Manager and Monitor; Dr Carlos Barrios — LACOG Executive Director; Fernanda Schwyter -LACOG Fundraising Coordinator; Dr. Ana Gelatti — Oncologist and researcher at the CPO; and Virgínia Webber — Clinical Research Manager at the CPO.
Oncology Workshop for Journalists at the Breast Cancer Congress, Gramado 2016.
The Cura Project was launched in Salvador at the BEST Of ASCO 2016 Annual Meeting, organized by LACOG. At the time, a presentation of the project was given by its recruitment coordinator, Fernanda Schwyter. The launch was accompanied by doctors Dr. Carlos Barrios (RS), Dr. Fernando Maluf (SP), Dr. Sergio Jobim de Azevedo (RS), Dr. Aknar, Freire de Carvalho Calabrich (BA), Dr. Carlos Sampaio (BA), Dr. Caio Rocha Lima (USA) and Dr. Mohammed Jahanzeb (USA).
The new knowledge produced by research changes our way of living and our culture. A clear example of this is the discovery of the association between smoking and lung cancer identified in 1965 by Professor Austin Bradford Hill. Over the years, our society incorporated this technical knowledge into its common sense, changing our way of thinking and our behavior.
Nowadays, cigarette advertisements are regulated and smoking is no longer allowed in public places. There are many benefits that this behavior change brought to our society: a reduction in the incidence of heart attacks, cerebrovascular accidents (strokes), and sick children due to exposure to passive smoking.
Why should Brazil (LATIN AMERICA), a country (ONE REGION) with so many basic health problems, with problems of lack of sanitation and education, invest in cancer research? Isn't this for countries that have already overcome these difficulties?
Because it will be the leading cause of death for years to come. Carrying a great social and economic impact. It is unquestionable that Latin American countries need to solve important social and public health problems, such as access to basic health, sanitation, and education. However, investments cannot be focused only on these areas, as this way we would be taking away from our cancer patients the possibility of having access to the latest scientific advances that benefit patients around the world. The probability of dying after a cancer diagnosis is twice as likely in Latin America as in the United States or Europe. This reality can only be changed by facilitating access to the new treatments that are now available thanks to research. Thus, the resources allocated for research development are converted into direct benefits for the population, opening opportunities for access to state-of-the-art treatments that are not funded by public health systems (and, often, because they deal with new drugs, are not available even in private systems). Research and the production of local knowledge are the main weapons to change the condition of our continent, where most patients receive lower treatments than those received elsewhere.
Because it is the only way to discover new drugs to combat the various types of cancer that decimate lives and burden society socially and financially in general. Initially, there is laboratory research, where the scientist is in a laboratory developing and testing drugs, remedies to cure diseases. This initial process usually takes more than 10 years before being tested on humans. And there is clinical research, which is testing the medicine on human beings. It is through research that doctors find new and better ways to help the population prevent, diagnose, control, and treat diseases. An example of this is the great evolution of cancer treatment seen in the last 50 years and which benefits us all. The disease, which was considered a sentence of death and suffering, now presents new perspectives: we are curing more and more patients and, above all, improving their quality of life.
However, we still need to do a lot, generate more knowledge and develop more effective drugs to face the enormous challenge of cancer, especially those types regionalized in developing countries, which are not covered by global research).
In this process, the patterns and characteristics of the diseases are observed and new diagnostic procedures and treatments are tested. It is where the doctor observes not only the disease, the cell, the tumor, but especially the PATIENT, the HUMAN BEING.
Follow CURA on social media
© 2023 Cura Project Institute. All rights reserved.
%2015.02.57_4c2bec24.jpg)
